AUS
NZ
UK
CA
USA
IND
A leading private healthcare provider across Australia, Healthscope Limited (ASX:HSO) has updated the market about multiple ownership changes on 25 March 2019.
The company has announced about the change of interests in its substantial holder, NorthWest Healthcare Properties Real Estate Investment Trust (NWH).
The interests of NorthWest Healthcare Properties Real Estate Investment Trust before the notice included 176,320,138 fully paid ordinary shares with the voting power of 10.13%. The company, with effect from 18 March 2019, owns 201,064,484 fully paid ordinary shares with the voting power of 11.55%.
Further, the company notified a change of interests in substantial holder, ANZ hospitals Pty Ltd (Bidco) on behalf of its ultimate controller, Brookfield Asset Management Inc. (BAM) and its other controlled entities listed in Annexure A. The interests of ANZ hospitals Pty Ltd (Bidco) before the notice included 176,320,138 fully paid ordinary shares with the voting power of 10.13%. The present notice with effect from 18 March 2019 reflects 201,064,484 fully paid ordinary shares with the voting power of 11.55%.
The company has also notified about Norges Bankâs ceasing to exist being companyâs substantial holder, effective 21 March 2019.
Recently, the company released its H1 FY19 report ending 31 December 2018. At the end of the period, the Revenue from ordinary activities stood at $1,224.6 million. The Profit from ordinary activities after tax attributable to members stood at $66.9 million. The cash and cash equivalents at the end of the period, as on 31 December 2018 stood at $108.7 million.
The stock of the company traded flat during the dayâs trading session (as on 25 March 2019) and stood at A$2.430, without any further changes. The market capitalisation of the company stood around A$4.23 billion, with circa 1.74 billion shares outstanding. HSO has offered a decent YTD return of 10.96%.
A world leader in developing innovative cellular medicines, Mesoblast Limited (ASX:MSB) updated the market on 25 March 2019 that its licensee JCR Pharmaceuticals Limited (JCR) in Japan had filed to extend market approval of TEMCELL®1 HS Inj. to be utilized among patients suffering from Epidermolysis Bullosa (EB).
TEMCELL has gained approval to treat severe graft versus host disease (aGVHD). Both MSB and JCR have amended their License Agreement so that JCR gains access to MSBâs mesenchymal stem cell (MSC) wound healing patents. Several genetic and symptomatic variants of EB had been noted so far. EB has been noticed as painful and frequently pervasive and debilitating, and in a few cases lethal, if the patient is below thirty years.
Recently, the company had updated the market about Mr Joseph R. Swedish being appointed as Non-executive Chairman of the MSB. His appointment is followed by the retirement of Mr Brian Jamieson on 31 March 2019.
The company had recently released financial results and operational highlights for the first half ending 31 December 2018. IN FY2019 period, MSB had conducted two end-of-phase meetings with FDA regarding the clinical and manufacturing aspects of the emerging BLA for remestemcel-L in the United States of America, and it would be utilized in kids suffering from steroid-refractory aGVHD. At the end of the period, as on 31 December 2018, the pro-forma cash held by MSB stood at US$92.0 million.
On 19 February 2019, MSB declared that it had reached close to the completion of its Phase 3 trial of heart failure product candidate.
By the closure of the trading session as on 25 March 2019, the stock of the company stood at A$1.415, up by 2.166% from its previous close. Its market capitalization stands at around A$690.6 million with circa 498.63 million shares outstanding. MSB has offered a decent YTD return of 9.49%.
Disclaimer
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.
